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Abstract
E.coli Aspartate transcarbamoylase (ATCase) is the allosteric enzyme that catalyzes the 
committed step of the de novo pyrimidine biosynthesis pathway.  ATCase facilitates the reaction 
between L-aspartate and carbamoyl phosphate to form N-carbamoyl-L-aspartate and inorganic 
phosphate.  The holoenzyme is a dodecamer, consisting of two trimers of catalytic chains, and 
three dimers of regulatory chains.  ATCase is regulated homotropically by its substrates, and 
heterotropically by the nucleotides ATP, CTP, and UTP.  These nucleotides bind to the regulatory 
chains, and alter the activity of the enzyme at the catalytic site.  ATP activates the rate of 
ATCase’s reaction, while CTP inhibits it.  Additionally, UTP and CTP act together to inhibit the 
enzyme synergistically, each nucleotide enhancing the inhibitory effects of the other.  Two classes 
of CTP binding sites have been observed, one class with a high affinity for CTP, and one with a 
low affinity.  It has been theorized that the asymmetry of the binding sites is intrinsic to each of 
the three regulatory dimers. It has been hypothesized that the second observed class of CTP 
binding sites, are actually sites intended for UTP. 
To test this hypothesis, and to gain more information about heterotropic regulation of ATCase 
and signal transmission in allosteric enzymes, the construction of a hybrid regulatory dimer was 
proposed.  In the successfully constructed hybrid, each of the three regulatory dimers in ATCase 
would contain one regulatory chain with compromised nucleotide binding. This project reports 
several attempts at constructing the proposed hybrid, but ultimately the hybrid enzyme was not 
attained.
This project also reports preliminary work on the characterization of the catalytic chain 
mutant D141A.  This residue is conserved in ATCase over a wide array of species, and thus was 
mutated in order to ascertain its significance.
vAbbreviations Used
ATCase Aspartate transcarbamoylase
T state Tense state, or the low-affinity, low-
activity conformation of ATCase
R state Relaxed state, or the high-affinity, high-
activity conformation of ATCase
CA Carbamoyl aspartate
PPi Inorganic phosphate
CP Carbamoyl phosphate
ASP L-aspartate
WT Wild-type aspartate transcarbamoylase
[S] 0.5 Half Saturation point
Vmax Maximum velocity
PALA N-phosphonacetyl-L-aspartate
K60E/K94E ATCase regulatory chain with the 
mutations  Lys60Glu and Lys94Glu
IPTG Isopropyl--D-thiogalactopyranoside
SDS Sodium Dodecyl Sulfate
PAGE Polyacrylamide Gel Electrophoresis
CHAPTER 1
Introduction
2“We must not forget that when radium was discovered no one knew that it would 
prove useful in hospitals.  The work was one of pure science.  And this is a proof that 
scientific work must not be considered from the point of view of the direct usefulness of it.  
It must be done for itself, for the beauty of science, and then there is always the chance 
that a scientific discovery may become like the radium, a benefit for humanity.”
-Marie Curie
At its most fundamental level, science is a source of truth, and an attempt to 
expand man’s understanding of the universe.  The pursuit of scientific truth extends back 
into history as far as the philosophers of ancient Greece, and is woven together by society 
with truths derived from philosophy, religion, and art.  The scientist looks at the world as 
a puzzle, and approaches this puzzle with the belief that a solution exists, and a firm 
commitment to discovering the solution.  Scientists may be motivated by “the excitement 
of exploring new territory, the hope of finding order, and the drive to test established 
knowledge.”1
Outside of the academic community science is most valued for its practical 
contributions to society.  Science gives rise to technologies and medical advances which 
extend human life, and make it more comfortable and convenient.  The field of 
biochemistry applies scientific curiosity to life on earth, at its molecular level.  Looking 
at life this closely has affected the accumulation of an expansive volume of information 
about the way biological organisms function or malfunction.  It has also allowed for 
medical advances which are pertinent not just to a single organ or limb, but to every cell 
in the body.  Rational drug design to combat viruses or cancer, and the synthetic 
production of proteins which treat various diseases are among the accomplishments of 
biochemistry.
3One of the most important and interesting types of molecules to a biochemist is an 
enzyme.  Enzymes perform the crucial function of speeding up metabolic reactions to 
rates which can support life.  Enzymes interact exclusively with their specified substrates, 
and in this way the body is able to control which reactions take place.  Enzymology 
becomes more complicated when allosteric enzymes are considered.  In addition to 
control over which reactions take place, organisms need to control when, and how fast 
these reactions take place.  This is achieved through allosteric enzymes, which often have 
complex structures to carry out their multiple functions.  Aspartate transcarbamoylase 
from Escherichia coli is one of the most extensively studied allosteric enzymes, and can 
in many ways be considered a paradigm for regulatory molecules.
1.1 BASICS OF ASPARTATE TRANSCARBAMOYLASE
Aspartate transcarbamoylase is encoded by the pyrBI operon of Escherichia coli.  
This operon is regulated by the pyrimidine nucleotide uridine 5-triphosphate (UTP), in an 
attenuation control mechanism which allows transcription to proceed when 
concentrations of UTP are low2.  ATCase is a key enzyme in the synthesis of UTP.  
Therefore, the attenuation mechanism serves to help maintain a relatively stable pool of 
UTP by allowing ATCase to be transcribed only when additional UTP is needed.  
When the twelve polypeptide chains of ATCase are transcribed and translated, 
they assemble to form a dodecamer.  The quaternary structure of ATCase consists of six 
catalytic and six regulatory polypeptide chains3.  Each catalytic chain has a molecular 
weight of 33,000 Da, and each regulatory chain has a molecular weight of 17,000 Da.  
4The polypeptide chains are organized into two trimeric catalytic subunits and three 
dimeric regulatory subunits. The three dimensional arrangement of these subunits is 
shown below. 
Figure 1. View of Aspartate transcarbamoylase along the threefold axis.4
The enzyme’s active sites are located at the junctions between the catalytic 
chains.  This amounts to three active sites per catalytic trimer, and six per molecule.  
Each active site contains a domain for each of the enzyme’s two substrates, L-aspartate 
(Asp), and carbamoyl phosphate (CP).  The catalysis of the reaction between these two 
molecules to form N-carbamoyl-L-aspartate and inorganic phosphate is the basic function 
of ATCase.  The carbamoyl group of carbamoyl phosphate is transferred to the -amino 
group of L-Asp.  This reaction is the first step unique to the pyrimidine biosynthesis 
pathway.  With the help of several other enzymes, carbamoyl aspartate, ATCase’s 
product, is eventually converted to UTP and to cytidine 5’-triphosphate (CTP).
5Figure 2. Mechanism of the reaction between carbamoyl phosphate and aspartate to form 
carbamoyl aspartate and inorganic phosphate
The binding of ATCase’s substrates is ordered.  Carbamoyl phosphate binds first 
to its site on the catalytic chain, and the binding of L-aspartate follows5.  The proposed 
mechanism for the reaction is that the leaving phosphate group of carbamoyl phosphate 
helps remove a proton from the NH2 group of aspartate.  This nitrogen can then readily 
attack the carbonyl carbon of CP.  The reaction then proceeds through a tetrahedral 
intermediate before the inorganic phosphate ion leaves6.  When the reaction is complete, 
the enzyme first releases carbamoyl-aspartate and second inorganic phosphate4.
1.1 HOMOTROPIC REGULATION
In 1965, Monod, Wyman, and Changeux proposed a model stating that allosteric 
enzymes exist in two conformational states that are in equilibrium with each other.  These 
states are known as the tense (T) state, and the relaxed (R) state.  The T state is 
characterized by a structural constraint which impedes ligand binding.  The R state 
represents a release from this structural constraint, allowing the ligand to bind to the 
molecule more easily7.  When no ligand is bound to the enzyme, the equilibrium is 
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shifted towards the T state.  However, ligand binding at even one subunit of a multi-
subunit enzyme causes a concerted transition from the T to the R state in all subunits.  
ATCase adheres to this model of global conformational change upon ligand binding8.  
For ATCase, the T to R transition involves an 11 Å expansion and rotation of the 
catalytic subunits about the enzyme’s 3-fold axis9 (Figure 3).  The aspartate and 
carbamoyl phosphate domains undergo domain closure, while the two domains of the 
regulatory chain undergo domain opening10.  The global change in quaternary structure is 
also accompanied by changes in the enzyme’s tertiary structure, which help to form the 
active site11.  The transition to the R state is essential to the formation of the fully 
catalytically effective active site.
Figure 3. T (left) and R (right) structural states of ATCase.  Catalytic chains are shown in red 
and regulatory chains are shown in grey.
The two state model accounts for the homotropic cooperativity and the sigmoidal 
kinetics of aspartate binding to ATCase.  When assays of the kinetic properties of the 
enzyme are performed, as the concentration of aspartate is steadily increased the 
7enzyme’s velocity increases in a manner that results in an “S”-shaped, or sigmoidal 
curve12.  
Figure 4. L-aspartate saturation curve resulting from a colorimetric assay performed in 0.05M 
Tris-acetate buffer at saturating concentrations of CP. Specific activity in mmoles N-carbamoyl-
L-aspartate formed per hour per mg of ATCase21
The sigmoidal shape can be explained by the fact that aspartate binds 
preferentially to the R state of the enzyme which causes a shift of the equilibrium towards 
the R conformation.  When a small amount of the substrate is present, it promotes the T 
to R transition.  The enzyme is then in its more active conformation, and so a more rapid 
increase in velocity is observed13.
A similar effect to positive cooperativity of substrate binding is observed when 
the bi-substrate analogue N-(phosphonacetyl)-L-asparate (PALA) binds to ATCase. 
PALA combines the structural features of both of the two natural substrates of the 
enzyme into one molecule.  Figure five illustrates the structural similarities.
Aspartate Saturation Curve
8Figure 5. Structures of N-(Phosphonacetyl)-L-Aspartate and the substrates of the reaction 
catalyzed by aspartate transcarbamoylase.15
PALA binds simultaneously to the CP and Asp site, and it binds about one 
thousand times more tightly than does carbamoyl phosphate.  This makes PALA a highly 
potent competitive inhibitor. 
PALA mimics the substrates of ATCase not only by binding at the same site, but 
also by causing the enzyme to undergo the same global conformational change from the 
T to the R state.  The binding of one PALA molecule to ATCase transforms all active 
sites to the more catalytically proficient R-state conformation.  Therefore, at low 
concentrations, PALA serves to activate the enzyme, increasing its maximal velocity of 
catalysis, rather than inhibiting it.    As concentrations of PALA increase, it out-competes 
CP at all of the active sites, and effectively prevents catalysis14.
91.3 HETEROTROPIC REGULATION: THE REGULATORY CHAINS
Aspartate transcarbamoylase’s catalytic subunits are of great importance because they 
carry out the catalysis of carbamoyl aspartate formation, and respond with great 
sensitivity to the presence of substrate.  However, its regulatory chains make ATCase 
more biochemically and metabolically interesting.  The regulatory chains determine the 
pattern of the heterotropic regulation of the molecule.  In a study done by Wild et. al. in  
1989, hybrid ATCase molecules were constructed that had catalytic chains from 
Escherichia coli and regulatory chains from Serratia marcescens.  The regulatory 
phenotype of this hybrid molecule was that of the S. marcescens, proving that it was in 
fact the regulatory dimers, and not the catalytic trimers which allow ATCase to be 
controlled by its heterotropic effectors, adenosine 5’- triphosphate (ATP) and cytosine 5’-
triphosphate (CTP)15.  Even without nucleotides bound, the regulatory chains place a 
certain amount of constraint on the catalytic chains.  Evidence for this is found in the fact 
that the maximum activity of the holoenzyme reaches only two thirds of the activity of 
the isolated catalytic trimer3. 
 ATCase’s nucleotide effectors bind to the molecule some 60 Å away from ATCase’s 
catalytic site, and yet they are able to cause changes which alter the way that substrates 
bind at the catalytic site16.  This characteristic raises questions about signal transmission 
in the enzyme.  The mechanism by which the nucleotides effect changes at the active site, 
and thereby modulate catalytic activity, is not well understood.  The study of ATCase’s 
regulatory chain can be seen as an opportunity to learn more about the ways in which 
information is passed from subunit to subunit within one molecule.  Additionally, the 
regulatory chains make possible control of the enzyme by feedback inhibition.
10
Like the catalytic chains, the regulatory chains have two functional domains.  The 
first is the allosteric domain where nucleotide effectors bind (Figure 6a).  The allosteric 
domain is formed by a ten-strand anti-parallel -sheet, flanked on one side by a row of -
helices (Figure 6b)17. The second domain is the zinc domain and is important for the 
affinity of the two regulatory chains in each regulatory subunit for each other, and for the 
complexing of the regulatory chains with the catalytic chains18.  There are six Zn2+ ions 
present per molecule of ATCase, and each zinc is coordinated to the molecule by the 
sulfhydryl groups of four cysteine residues.  The presence of Zn2+ is important to the 
stability of the molecule17.
The N-terminus of the regulatory chain also has several significant features.  It is 
important for preventing aggregation of regulatory chains, and evidence exists that it is 
involved in the formation of the nucleotide binding sites18.
a.       b.
Figure 6. a. View of the quaternary structure of ATCase with domains of the catalytic and 
regulatory chains labeled as followed al, allosteric domain; Zn, zinc domain; cp, carbamoyl 
phosphate binding domain; asp, aspartate biding domain b.View of the allosteric domains of a 
regulatory dimer (R1-R6).  Shown with CTP bound.18
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ATCase’s regulatory chains interact with the nucleotides CTP, UTP, and ATP, to 
affect a regulation of the molecule’s activity.  Understanding the binding characteristics 
of these ligands is important to the understanding of the enzyme’s mechanism.
ATP UTP CTP
Figure 7.  Moleular Structure of ATCase’s three nucleotide effectors
 Early studies of the binding of CTP to ATCase revealed the presence of six total 
binding sites for CTP, which could be divided into two discrete classes19.  One set of 
binding sites had a much greater affinity for CTP than the second site.  This was revealed 
by equilibrium dialysis studies, and the resulting Scatchard Plots which deviated from a 
straight line.  These plots were indicative of two classes of binding sites, one with high 
affinity and one with low affinity for CTP (Figure 8).
12
Figure 8. CTP binding isotherms plotted as r/(CTP) vs. r, where r is the number of moles of 
ligand bound per mole of enzyme and (CTP) is the concentration of free ligand20.
Winlund and Chamberlin found that not only was CTP binding heterogeneous to 
the ATCase holoenzyme, but it was heterogeneous to each regulatory dimer.  This meant 
that to each regulatory subunit, CTP could bind once with high affinity and once with low 
affinity.  However, whether or not the observed nonequivalence of the site was pre-
existing and due to some asymmetry in the polypeptide, or was induced upon binding of 
the first CTP molecule was unknown20.
The phenomenon in which it becomes harder for a ligand to bind with each 
subsequent ligand that is bound, is known as negative cooperativity.  CTP binding to 
ATCase is an archetypal example of this characteristic.  A proposed evolutionary reason 
for such a development is that it widens the range of ligand concentration which can be 
effective for regulation of the molecule.  A protein is most sensitive to effector 
concentrations which approximate the dissociation constant, Kd, of the protein-effector 
complex.  For this reason, the presence of two discrete classes of binding sites, with Kd’s 
13
that differ by at least an order of magnitude, greatly enhances the range of concentrations 
for which ATCase can be sensitive to the presence of CTP20.
Studies with UTP as a heterotropic effector revealed that UTP and CTP work 
together synergistically to inhibit the enzyme.  UTP on its own is not an effective 
inhibitor of ATCase.  However, when both pyrimidine nucleotides are present, they work 
together to inhibit activity to a greater extent than either of the two can independently.
a.
b.
Figure 9. Influence of nucleotide triphosphates on the activity of ATCase.  Colorimetric assays 
were performed  in 0.1 M imidazole-acetate buffer in the presence of increasing concentration of 
a) CTP, and b) CTP (open circles) and CTP and UTP (closed circles). 21
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 Based on this information, a theory was developed that explained the behavior of 
CTP and UTP in regards to ATCase.  The three so-called low affinity CTP sites are 
actually sites designated by ATCase for UTP.  By this measure, a full inhibition of the 
enzyme is only possible when both nucleotides are present to fill their sites.
ATP also has a regulatory effect on ATCase.  Rather than inhibiting the activity 
of the enzyme, ATP acts as an activator, increasing the enzyme’s activity12 (Figure 10).   
ATP and CTP show competitive behavior in binding to the regulatory chain, indicating 
that these two nucleotides bind at the same site. ATP however, binds to the site much less 
strongly than CTP.
Figure 10. Graph of kinetic data displaying the effect of ATP and CTP on reaction velocity.of 
ATCase.  Specific activity in units of mmols N-carbamoyl-L-aspartate produced per hour  per mg 
of protein.  Activating effect of ATP (red),  Aspartate saturation curve in the absence of any 
nucleotides  (blue),  Inhibiting effect of CTP ( green).
While it is clear that ATP, CTP, and UTP bind to and regulate aspartate 
transcarbamoylase, the mechanism by which they do so is ambiguous.  Homotropic 
regulation in ATCase adheres well to the two-state model proposed by Monod, Wyman, 
15
and Changeux.  Heterotropic regulation however, can not be described by this model as 
easily.  It remains unclear whether binding of nucleotide effectors brings about regulation 
by way of a global conformation change, and a shift in the T to R equilibrium caused by 
stabilization of one of the two forms of the enzyme, or by way of more localized 
structural changes that propagate the regulatory signal to the active site10.
1.4 METABOLIC CONTROL
The volume of information about aspartate transcarbamoylase which has been 
accumulated is immense.  What makes this molecule such a focal point of scientists’ 
attention?  One of the undercurrents of the study of ATCase is the theme of control.  
ATCase is controlled in three distinct and important ways.  The first of which is the 
attenuation control mechanism which allows ATCase to be transcribed from its gene only 
when UTP, the end-product of the pathway, is needed. This conserves resources, ensuring 
that the cell does not waste the energy required for the transcription and translation of a 
large macromolecule if it will not be immediately necessary.
The second mechanism of control is the homotropic regulation by the substrate 
aspartate.  Aspartate binds to ATCase with positive cooperativity, meaning binding is 
enhanced with each subsequent ligand bound.  ATCase is regulated by being shifted into 
a more active conformation, and increasing its maximal velocity when substrate is 
present.  Positive cooperativity gives a molecule the metabolic advantage of signal 
amplification.  ATCase is more sensitive, and can respond more efficiently to the 
presence of aspartate because of this property of homotropic regulation. 
16
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 The third way in which ATCase is controlled is by a mechanism known as 
feedback inhibition.  In feedback inhibition, an end product of a pathway imposes control 
by stopping the production of more of itself.  The production of CTP and UTP by 
ATCase is controlled by feedback inhibition (Figure 12) 12.
Figure 12. Schematic diagram of the feedback inhibition of pyrimidine biosynthesis in E.coli.  
Heavy broken arrow indicates feedback inhibition12.
Feedback inhibition dictates that additional end product is not made unless 
existing end product is being consumed.  This is beneficial to an organism because it 
conserves resources and prevents the excessive buildup of any given end product.
Analyzing the synergistic inhibition of ATCase by CTP and UTP within the 
context of feedback inhibition reveals a new layer of logic in the way that ATCase 
functions.  Elevated levels of CTP, in addition to the partial inhibition of ATCase, cause a 
full inhibition of the enzyme CTP synthetase, effectively shutting down the production of 
any more CTP.  However, ATCase is left partially active, and thus the production of UTP 
is still possible.  For the biosynthesis of UTP to be prevented, UTP levels must also be 
17
elevated, to complete the inhibition of ATCase22.  That ATP would activate ATCase is 
also logical.  Cellular levels of purine and pyrimidine nucleotides must be kept relatively 
even for organisms to be able to effectively produce nucleic acids.  Therefore, an excess 
of ATP, a purine nucleotide, indicates to the cell that more pyrimidines should be 
produced.  The fact that ATP competes for the same site as CTP, but binds much less 
strongly, ensures that regulation by ATP and CTP do not cancel each other out.  Cellular 
levels of ATP must be significantly higher than cellular levels of CTP in order to 
effectively inhibit ATCase.
The importance of metabolic control is most noticed in its absence.  When cells 
lose their ability to control their rate of growth and division, the result is cancerous 
growth.  Due to the fact that ATCase plays a crucial role in the production of nucleotides, 
creating a drug which could stop the catalytic activity of ATCase is an attractive 
possibility as a way to impose control upon cancerous cells.  Denying a cell the building 
blocks for DNA synthesis will stop its progress through the mitotic cycle.  As mentioned 
earlier, PALA is a highly potent inhibitor of ATCase.  For this reason it was given serious 
consideration as an antiproliferative drug, to be used in conjunction with an inhibitor of 
the pyrimidine nucleotide salvage pathway.  Studies were able to demonstrate that PALA 
could effectively inhibit de novo pyrimidine nucleotide synthesis in mammalian cells in 
culture23.  PALA’s toxicity prove to be too high for medicinal use, but it has sparked 
researchers to work towards the creation of a similarly effective, but less toxic inhibitor.  
18
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1.5 OBJECTIVES
In hopes of gaining more answers about the mechanism of signal transmission in 
the regulatory chain, the creation of a hybrid regulatory subunit has been proposed.  The 
hybrid would be composed of one wild-type regulatory polypeptide chain, and one which 
had been mutated so that it was incapable of binding any of the nucleotide effectors. This 
hybrid subunit would then be combined with wild-type catalytic trimers to reconstitute 
the holoenzyme.  An ATCase molecule in which half of the regulatory chains are non-
functional would afford us with the opportunity to observe the relationship between the 
two polypeptide chains which comprise the regulatory dimer. Kinetic studies done on the 
hybrid would potentially be able to answer several questions about nucleotide binding 
and effects, and signal transmission in allosteric enzymes. Such studies would allow for 
the examination of whether or not both CTP and UTP are able to bind and act as 
inhibitors and whether or not the enzyme is able to respond differently to these two 
nucleotides, whether or not ATP can still bind and activate the enzyme, and finally, 
whether or not proper functioning of both subunits of the regulatory dimer is essential to 
signal transmission through the molecule.
Figure 13. Schematic representation of regulatory chain hybrids.  Holoenzyme consists of two 
catalytic chain trimers, and three regulatory dimers, (two are shown) composed of one wild type 
(WT) and one mutant (M) regulatory chain.
19
Previous work in the Kantrowitz lab has made many attempts at the creation of 
regulatory chain hybrids.  In this project, several new strategies were conceived in hopes 
of successfully attaining the hybrid.  The first of these strategies was the creation of a 
plasmid which contained a histidine tail attached to the N-terminus of a wild type 
regulatory chain gene, followed by a double mutant regulatory chain gene.  The theory 
was that because the two genes would be translated by the same ribosome, one 
immediately following the other, at their formation the two protein monomers would be 
in close proximity to each other.  They therefore would have a high likelihood of 
dimerizing as a hybrid.  The histidine tag would serve as a chromatographic handle 
aiding in the isolation of the hybrid molecule, which uniquely would have only one 
histidine tag (as opposed to two or zero in the wild type or mutant dimers, respectively). 
(Figure 14).
Figure 14. Cartoon Representing the three types of regulatory chain dimers which should 
form from the proposed plasmid.  Left, Mutant dimer, no histidine tags.  Middle, Hybrid 
dimer, one histidine tag.  Right,Wild type dimer, two histidine tags.
In a second approach, a signal sequence from the enzyme alkaline phosphotase 
(AP) was attached to the N-terminus of the ATCase regulatory chain.  In AP this signal 
sequence targets the enzyme to the periplasmic space of the bacteria.  To get to the 
periplasm the enzyme must be pulled through the cell membrane, one polypeptide chain 
at a time.  By co-transforming an E.coli cell with a plasmid containing a wild-type 
regulatory chain with a signal sequence, and a plasmid containing a mutant regulatory 
20
chain with a signal sequence, it seemed possible that wild-type and mutant regulatory 
chains could be pulled through the cell membrane as monomers, and would then dimerize 
to form a hybrid when they meet in the periplasm.  
A third strategy for creating a hybrid involved the synthesis of a small 
polypeptide designed to bind to the dimerization domain of the regulatory chain, and 
therefore block the formation of a regulatory chain dimer.  If dimerization of wild-type 
enzyme could successfully be blocked, it might then be possible to use mutant regulatory 
chain in a high molar excess to out-compete the peptide for the binding site, and form a 
hybrid dimer.
Finally, experiments were conducted using only EDTA to promote 
monomerization.  Wild-type and mutant monomers were then combined, in an 
environment that would fascilitate re-dimerization, in hopes that this procedure would 
yield some hybrid dimers.
Due to the fact that the hybrid project was unsuccessful, a second project was 
begun.  This second, less extensive project, is the kinetic characterization of a catalytic 
chain mutant of ATCase.  Evolutionarily conserved residues in ATCase were searched 
for and located by the Kantrowitz group through extensive comparison of the ATCase 
amino acid sequences from many different species. Residues which remain unchanged 
across a spectrum of organisms ranging from bacteria to humans are assumed to have a 
functional significance. The goal of this project is to mutate these residues and then 
examine the changes in the enzyme’s behavior.  Colorimetric assays of the mutant 
enzyme’s kinetic behavior should help reveal whether or not the conserved amino acid in 
question is critical to any of the functions of aspartate transcarbamoylase.  
21
CHAPTER 2
Materials and Methods
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Materials—Adenosine-5’-triphosphate, agar, agarose, ammonium persulfate, ampicillin, 
bromophenol blue, cytidine-5’-triphosphate, L-aspartic acid, nickel sulfate, sodium 
chloride, sodium dodecyl sulfate, sodium EDTA, sucrose, and 2-mercaptoethanol were 
purchased from Sigma Chemical Co.  Tris was purchased from MP Biomedicals.  2,3-
butanedionemonoxime was purchased from Acros Organics.  Dialysis tubing, glacial 
acetic acid, hydrochloric acid, sulfuric acid, tryptone, and yeast extract were purchased 
from Fisher Scientific.  Q-Sepharose Fast Flow (QFF) resin was purchased from 
Pharmacia.  Bis, coomassie blue, TEMED, and UnoSphere Q Ion Exchange resin was 
purchased from BioRad.  Acrylamide and enzyme grade ammonium sulfate were 
purchased from ICN Biomedicals.  Kanamycin sulfate was purchased from USB 
Corporation.  Chelating Sepharose Fast Flow was purchased from Amersham 
Biosciences.  Oligonucleotide primers and reagents for DNA purification and gel 
extraction were purchased from Qiagen and were used according to supplier’s 
recommendations.  Restriction endonucleases and T4 DNA ligase were purchased from 
New England Biolabs.
Strains — E. coli strain EK1611 [(mcrA)183, (mcrCB-hsdSMR-mrr)173, endA1, 
supE44, thi-1, recA1, gyrA96, relA1, lac/F’ proAB, laclqZM15, Tn10(Tetr)], based on 
XL1-Blue MRF’ was obtained from Stratagene (La Jolla, CA).  The strain BLR(DE3) [F-
dcm ompT hsdS(rB-mB-) gal (DE3)] was also obtained from Stratagene.  The strain 
EK1594 [F- ara, thi, pro-lac, pyrB, pyrF±, rpsL (DE3)] was previously constructed in 
this laboratory.   
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Methods—Construction of a plasmid containing a histidine tag on the N-terminus of the 
wild-type pyrI gene, followed by the mutant pyrI gene, K60E/K94E.
The E. coli ATCase plasmid pEK67 carries the wild-type pyrI gene, preceded by 
a sequence coding for a histidine tag.  It is controlled by a T7 promoter allowing for 
protein over-expression in the presence of IPTG, and contains a gene for kanamycin 
resistance. Plasmid pEK599 carries the E. coli regulatory chain double mutant 
K60E/K94E, known to exhibit compromised nucleotide binding, and a -4 charge 
difference from the wild-type enzyme when reconstituted with the catalytic subunits.

Figure 15.  Cartoon of plasmid containing a wild-type pyrI gene with a histidine tag at the N-
terminus, followed by a double mutant pyrI gene
In order to construct a plasmid with a histidine tag followed by wild-type pyrI and 
double mutant pyrI, the two plasmids were digested with restriction enzymes NdeI and 
XhoI and electrophoresed on a 1% agarose and ethidium bromide gel.  The larger 
fragment from pEK647 and the smaller fragment from pEK599 were cut out of the gel 
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and ligated using T7 DNA ligase.  EK1611 competent cells, designed for plasmid over-
expression were then transformed with the ligated DNA and grown overnight on a YT-
kanamycin plate.  A colony was then selected from this plate and a 5 mL culture of YT 
media with 0.05 mg/mL kanamycin was grown overnight.  The desired plasmid was 
purified from this culture using a Qiagen plasmid prep kit.  Competent BLR cells were 
then transformed with the new plasmid. The strain BLR contains a deletion in the recA 
gene, which serves to prevent homologous recombination and provides high-level protein 
expression.  Transformed BLR cells were plated on YT-kanamycin plates.  Single 
colonies were then used to make 5 mL overnight cultures.  The overnight cultures were 
used to inoculate 2L of YT-media with kanamycin.  Cells were grown at 37° to 
approximately A566= 0.6, and then over-expression of the protein was induced by addition 
of 0.4 mM isopropyl-beta-D-thiogalactopyranoside (IPTG).  The culture then continued 
to grow overnight to an optical density of about 1.2, allowing for the cells to reach 
stationary phase.  The culture was harvested by centrifugation (5000 rpm for 20 minutes).
The pellets were re-suspended in 40 mL of ice-cold lysis buffer (0.1 M Tris-Cl, 0.1 mM 
zinc acetate, pH 8.3).  The cells were then disrupted by sonication for 10 cycles of 30-
second intervals at 50% duty.  This process breaks the cell wall and releases intercellular 
proteins.  The lysate was then centrifuged at 15000 rpm for 20 minutes. The pellet, which 
contained the cellular membranes, membrane proteins, DNA, and RNA was discarded.  
The supernatant contained cellular proteins.
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Purification of regulatory chain hybrids using immobilized metal affinity 
chromatography (IMAC).
A nickel affinity column was prepared by washing the chelating sepharose fast 
flow column, first with distilled water, then with a 0.3 M nickel sulfate solution in order 
to apply the nickel to the column.  Excess nickel was rinsed off with water.  Several 
column volumes of binding buffer (0.05M Tris-HCl, 0.5M NaCl, pH 7.0) were then 
applied to the column.   The mixture of cellular proteins which was the supernatant after 
the sonication step was then carefully applied to the prepared IMAC column. The 
immobilized nickel chelates the histidine tag on the proteins of interest.  The column was 
once again rinsed with binding buffer to remove any non-bound protein.  Protein of 
interest was eluted using an imidizole containing elution buffer.  First a 0.05 M imidizole 
buffer was used for more weakly bound proteins, (0.05 M Tris-HCl, 0.05 M imidizole, 
0.5 M NaCl, pH 7.5). and second a 0.4 M Imidizole Buffer was applied in order to elute 
any proteins that may have been bound more strongly.  The material being eluted from 
the column was collected in fractions.  The fractions were then analyzed by 15% native 
polyacrylamide gel electrophoresis (PAGE).
Construction of a plasmid containing an alkaline phosphotase signal sequence attached 
to the pyrI gene.
The E. coli ATCase plasmid pEK592 contains the wild-type pyrI gene.  The 
alkaline phosphotase (AP) plasmid pEK196 contains the wild-type gene for AP, which is 
preceded by a signal sequence that targets AP for the periplasm.  In order to transfer this 
signal sequence to the ATCase regulatory chain, the wild-type pyrI gene was cut from 
pEK592, and used to replace the wild type AP gene in pEK 196  (Figure 16).  The two 
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plasmids were digested with restriction enzymes Xma1, and Xho1, and electrophoresed 
on a 1% agarose gel stained with ethidium bromide.  The larger fragment from pEK196 
and the smaller fragment from pEK592 were cut out of the gel, excess agarose was 
dissolved according to the protocol of the Qiagen QlAquick gel extraction kit, and the 
DNA fragments were ligated using T7 DNA polymerase. 
EK1611 competent cells were transformed with the ligated DNA, and 
successfully transformed cells were selected for on a YT-ampicillin  plate.  5 mL 
overnight cultures were prepared from single colonies, and the desired plasmid was 
isolated from these cultures according to the protocol of the Quiagen Mini-Prep kit.  
EK1594 competant cells, a cell line which has the gene for ATCase deleted on its 
chromosome, were then transformed with the newly prepared plasmid, pEK649.  
Successfully transformed cells were selected for on a YT-ampicillin plate.  

Figure 16.  Cartoon depiction of plasmids and restriction enzymes required to create a plasmid 
with the AP signal sequence attached to a wild-type pyrI gene.
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5 mL overnight cultures were prepared from single colonies.  The overnight 
cultures were used to inoculate 50 mL trial cultures of YT-media with ampicillin.  At an 
A566 of 0.6, trial cultures were induced with 0.4 mM IPTG and allowed to grow either for 
4 hours at 37° or overnight at 25°.   After the growth period, cells were harvested by 
centriguation at 5000 rpm for 20 minutes.  The pellet was then resuspended in buffer 
containing 20% sucrose, 0.03 M Tris, 0.005 M EDTA, pH 7.4.  The cells were then 
vortexed for five minutes and centrifuged for five minutes.  The supernatent was 
removed, and the pellet was resuspended in cold water, vortexed, and centrifuged.  This 
procedure is known as osmotic shock, it allows for the isolation of all proteins in the 
periplasmic space of a gram negative bacterium, while leaving the intracellular 
membrane in tact with all cytoplasmic proteins sequestered inside.  At the end of the 
procedure the contents of the periplasm is in the supernatent, while the rest of the cell 
remains in the pellet.  The cells in the pellet were then resuspended in Low Q buffer (50 
mM Tris-acetate, 2 mM 2-mercaptoethanol, 0.1 mM zinc acetate pH 8.3), and subjected 
to sonication for 9 cycles of 30 second intervals at 50% duty. The lysate was then 
centrifuged at 15000 rpm for 20 minutes, and the supernatent containing the cytoplasmic 
proteins was saved.  An identical osmotic shock followed by isolation of periplasmic and 
cytoplasmic proteins procedure was perfomed on cells that overexpressed the pyrI gene 
without a signal sequence attached.  The protein isolated from these cells served as a 
control.  The four protein samples, periplasmic, cytoplasmic, control periplasmic, and 
control cytoplasmic, were analyzed by 15% Sodium dodecyl sulfate (SDS)-PAGE. SDS 
is an anionic detergent that coats proteins with a negative charge proportional to its 
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molecular weight.  Each protein’s electrophoretic mobility is thus dependent only on its 
molecular weight, simplifying analysis.
Blocking dimer formation with a synthetic polypeptide
A member of the Kantrowitz Laboratory synthesized the pentapeptide Isoleucine-
Threonine-Isoleucine-Glycine-Leucine.  The polypeptide was designed to mimic the 
interface of regulatory chain dimerization.  Examination of the sequence of the 
pentapeptide and of the regulatory chain showed that the pentapeptide would form six 
hydrogen bonds with the regulatory chain at the interface.  Wild-type regulatory chain 
enzyme was mixed with varied ratios of polypeptide in molar excess and with 10 mM 
EDTA.  The mixture was allowed to equilibrate overnight at 4°C.  The mixture was then 
electrophoresed on a 15% native gel to visualize any band shifts as a result of addition of 
the polypeptide or of EDTA.  
Sucrose Density Gradient Experiments
In order to determine more conclusively if the polypeptide caused the protein to 
exist as a monomer, sucrose gradients were created ranging from 6 to 20 % sucrose.  20 
% sucrose was first added to a centrifuge tube, and then an equal volume of the 6 % 
sucrose was carefully added on top of the 20 % sucrose.  A small volume of regulatory 
chain enzyme or enzyme mixed with the polypeptide, or with the polypeptide and EDTA, 
was added carefully to the top of the sucrose gradient.  Separate tubes with the enzymes 
carbonic anydrase (29kDa) and myoglobin (17kDa) were also prepared to use as 
molecular weight standards.  All tubes were then centrifuged at 47,000 rpm for 20 hours.  
At the end of the 20 hour period, a hole was poked in the bottom of the tube, and a 
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solution of crystal violet blue dye was used to push the contents out of each tube and 
transfer it sequentially into 200 µL wells.  The absorbance at 595 nm of each well was 
then read, providing data about where in the tube protein was located.   Additional trials 
of this experiment were performed with varied concentrations of EDTA mixed with the 
regulatory chain enzyme.
EDTA dialysis experiments
Wild-type and K60E/K94E double mutant regulatory chain protein were 
combined in 60 µL dialysis buttons and allowed to dialyze overnight at 4°C against 1 L 
of a buffer containing 10 mM EDTA, 50 mM Tris-acetate, and 2 mM 2-mercaptoethanol, 
pH 8.3.  Following dialysis in buffer with EDTA, the dialysis buttons were transferred to 
1 L of a buffer containing 0.1mM zinc-acetate, 50 mM Tris-acetate, and 2 mM 2-
mercaptoethanol, pH 8.3.  Samples were dialyzed in this second buffer overnight at  4°C.  
Following dialysis in each buffer, protein samples were electrophoresed on 12% native 
gels for visualization of band shifting.
Protein purification
All ATCase regulatory chain enzyme for the polyptide, sucrose gradient, and 
EDTA dialysis experiments was purified according to the following method: EK594 
competent cells are transformed with pEK592 or pEK599, and are plated on YT-
ampicllin plates. A 5 mL overnight culture in YT media with 0.15 µg/mL ampicillin.   2 
L of YT-media with 0.15 µg/mL ampicillin is inoculated with 1 mL of the overnight 
culture. The culture is grown at 37˚ to A566 of 0.6 and then over-expression of the 
regulatory chain protein is induced by addition of 4mM IPTG.  Growth is allowed to 
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continue over night until cells reach A566 of approximately 1.2.  The culture is then 
harvested by centrifugation (5000 rpm for 20 minutes).  The pellets are re-suspended in 
40 mL of ice-cold lysis buffer (0.1 M Tris-Cl, 0.1 mM zinc acetate, pH 8.3).  The cells 
are then disrupted by sonication on ice for 10 cycles of 30-second intervals. The lysate is 
then centrifuged at 15000 rpm for 20 minutes.   Ammonium sulfate is slowly added to  
the supernatent to 65% saturation (0.431 g/mL) at 4ºC while stirring.  E. coli ATCase 
precipitates at this concentration of salt, facilitating separation from other proteins which 
precipitate at higher saturation.  Centrifugation concentrates the precipitated protein into 
the pellet.  The pellet is then dissolved in 50 mM Tris-acetate, 2 mM 2-mercaptoethanol, 
0.1 mM zinc acetate (pH 8.3).  The re-dissolved pellet is dialyzed for 24 hours with two 
buffer changes, which served to remove the ammonium sulfate from the protein.  
Following dialysis, anion-exchange chromatography with a QFF column was performed 
and the pooled fractions were analyzed by SDS-PAGE. A280 was recorded for each 
fraction and the location of the desired protein was identified.  The corresponding 
fractions were collected, and protein concentration could then be determined via UV 
spectroscopy at 280 nm.  Protein was stored at 4ºC.
Colorimetric Assays
All assays of the enzyme’s kinetics are performed according to the following 
procedure:  All reagents except for carbamoyl phosphate are added to disposable glass 
culture tubes.  Tubes are placed in a 25˚ C water bath.  Carbamoyl phosphate is added to 
the tubes sequentially, and the tubes are vortexed.  Tubes are incubated for 10 minutes, 
and then acid quenched with 1 mL of ice cold color mix (50 % sulfuric acid, 5 % acetic 
acid, 300 mg 2,3-butanedionemonoxime).  Tubes are then immediately stoppered and 
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placed in a box protected from light.  A set of standards is prepared which can be 
quenched with no time limit.  The box is placed in a dark drawer overnight at room 
temperature.  After the assay is allowed to develop overnight, the tubes are one by one 
unstoppered and placed into a 45˚ water bath with a fluorescent light positioned directly 
above them.  The tubes incubate in the water bath for 24 minutes.  At the end of this 
period, the tubes are re-stoppered and placed into an ice filled box that is protected from 
light.  A466 of the tubes is then determined.  The spectrophotometer is blanked with water.
The assay measures the amount of carbamoyl aspartate that the enzyme is able to 
produce in 10 minutes.  Carbamoyl aspartate reacts with the color mix to produce color 
with absorbance at 466 nm in proportion to the amount of carbamoyl aspartate present.  
In the standards, a set amount of carbamoyl aspartate is added to each tube.
Aspartate saturation curve
Added to each reaction tube was L-aspartate, ranging in concentration from 0 to 60 mM, 
0.86 µg D141A mutant ATCase in 500 µL of 0.1M Tris-acetate buffer pH 8.3, 100 µL of 
48mM carbamoyl phosphate, water to raise volume to 1 mL. 
CTP saturation curve
Added to each reaction tube was CTP, ranging in concentration from 0 to 2.0 mM, 3.08 
µg D141A mutant ATCase in 500 µl of 0.1M Tris-acetate buffer pH 8.3, 100 µl of 48 
mM carbamoyl phosphate, 100 µL of 40 mM aspartate, water to raise volume to 1mL.
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ATP saturation curve
Added to each reaction tube was ATP, ranging in concentration from 0 to 4.0 mM, 1.54 
µg D141 A mutant ATCase in 500 µL of 0.1 M Tris-acetate buffer pH 8.3, 100 µL of 48 
mM carbamoyl phosphate, 100 µL of 40 mM aspartate, water to raise volume to 1 mL.
Standard Curves
Added to each reaction tube was carbamoyl aspartate ranging in concentration from 0 to 
0.12 mM, 500 µL of 0.1 M Tris-acetate buffer pH 8.3, and water to raise volume to 1 mL.
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CHAPTER 3
ATCase Regulatory Chain Hybrid Project: Results & Discussion
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This project reports that the proposed aspartate transcarbamoylase regulatory 
chain hybrid was not successfully created.  In the various methods employed in the 
pursuit of the hybrid, several loose ends can be found. The possibilities for creation of a 
regulatory chain hybrid were not exhausted by this project.  However, after extensive and 
prolonged efforts by the Kantrowtiz lab, a decision was made that continued labor on the 
problematic hybrid construction would not be the most efficient use of the lab’s temporal 
or financial resources.  For this reason, work on the multiple approaches to the hybrid 
was cut short.
Use of a histidine tag as a chromatographic handle
In order to create the plasmid containing a histidine tag on the N-terminus of the 
wild-type pyrI gene, followed by the mutant pyrI gene K60E/K94E a restriction digest 
was performed on the plasmids pEK647 and pEK599.  After digestion with NdeI and 
XhoI the vectors were electrophoresed on a 1% agarose/EtBr gel.  Figure 17 depicts the 
resulting fragments.
Lane
1 2 3 4 5 6
Figure 17.  1% Agarose/EtBr gel electrophoresis of the restriction digest products of vector 
pEK647 with NdeI and XhoI (lanes 1 and 2), pEK647 undigested (lane 3), the digest products of 
pEK599 with NdeI and XhoI (lanes 4 and 5), and pEK599 undigested (lane 6).  
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 The lesser mobility of the uncut fragments indicates that the digest was 
successful.  The two larger (top) pieces of DNA from the pEK647 digest (lanes one and 
two), along with the smaller (bottom) piece of DNA from the pEK599 digest (lane five) 
were excised from the gel purified, and ligated.  The digest product in lane four was not 
used because the bands were not distinct.  The success of the ligation was confirmed by a 
second restriction digest in which the newly created plasmid was cut either zero, one, or 
two times and these products were run on an agarose/EtBr gel for comparison.  As Figure 
18 illustrates, the uncut plasmid runs the shortest distance; the single cut plasmid travels 
slightly farther due to the greater ease of mobility of a linear DNA fragment as compared 
to a circular fragment.  The double cut plasmid travels the furthest through the gel 
because a small piece of the vector, (the double mutant pyrI gene) has been cut away 
from the rest of the DNA.  The lowered molecular weight of this fragment allows it to 
travel the furthest.
Lane
1 2 3
Figure 18.  1% Agarose/EtBr gel electrophoresis of the NdeI and XhoI digest of plasmid pEK 
648 (lane 1), the NdeI digest of plasmid pEK648 (lane 2), and plasmid pEK648 on its own.
After BLR competent cells were transformed with the successfully prepared 
plasmid, this cell line was used to over-express the wild-type and mutant ATCase 
regulatory chain protein encoded by the plasmid.  In order to purify the ATCase 
regulatory chain protein, a nickel affinity column was used.  Protein containing fractions 
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collected from the column were electrophoresed on a native polyacrylamide gel which is 
depicted below.
Lane
1 2 3 4 5 6 7 8 9
Figure 19. 15% Native PAGE of the crude protein extract which was loaded onto the nickel 
affinity column (lane 1), protein which did not stick to the column (lane 2), protein eluted after 
the addition of 0.05 M imidazole (lanes 3, 4, and 5), protein eluted after the addition of 0.4 M 
imidazole (lanes6, 7, and 8), and a wild-type regulatory chain standard (lane 9).
This gel revealed the absence of a band which would indicate the successful over-
expression of the mutant regulatory chain protein.  The K60E/K94E mutant is known to 
run lower on a native polyacrylamide gel than does the wild-type protein.  A bulk of 
protein from the crude sample lines up with the wild-type standard, however there is no 
large band which runs lower than the wild-type protein.  If the experiment had gone 
ideally, we would have looked to see large bands from wild-type and mutant protein, and 
a smaller band from the hybrid dimer.  The hybrid dimer, with one histidine tag would be 
eluted with a lower concentration of imidizole than was necessary to elute the wild-type 
dimers, which each possess two histidine tags.  Without over-production of the mutant 
enzyme however, the possibility of hybrid formation is categorically excluded.  This 
result was confirmed by a second attempt to grow and purify the protein encoded by the 
newly created plasmid (Figure 20).
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Lane
1 2 3 4 5
Figure 20.  15% Native PAGE of the crude protein sample loaded onto the nickel affinity 
column (lane 1), protein which did not stick to the column (lane 2), protein eluted by 0.05M 
imidizole (lanes 3 and 4), and wild-type ATCase regulatory chain standard (lane 5)
This gel again illustrates that the crude protein sample contains a large amount of 
wild-type regulatory chain protein, as the large bands in lanes one and two line up with 
the standard in lane five, however there is no significant presence of any other protein.
The approach towards creating a regulatory chain hybrid by way of a plasmid 
containing a histidine tag attached to a wild-type pyrI gene, followed by the K60E/K94E 
mutant pyrI gene was unsuccessful. The results showed that while the histidine tag was 
able to isolate the wild-type ATCase regulatory chain protein from the bulk of the protein 
collected from the E.coli cells, the K60E/K94E mutant protein was not successfully over-
expressed. A potential reason for this failure is an unforeseen problem with the plasmid 
sequence that interferes with the mechanism of transcription of the second pyrI gene.
Alkaline phosphotase signal sequence as a means of exporting regulatory chain 
monomers to the periplasm
In order to construct a plasmid coding for a wild-type ATCase regulatory chain 
protein with an alkaline phosphotase signal sequence attached, a double restriction digest 
of the plasmids pEK196 and pEK592 was performed.  The products of this digestion 
were electrophoresed on a 1% agarose/EtBr gel.  The resulting band pattern is displayed 
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in Figure 21.  From lane one, the top band — the larger vector fragment containing all of 
pEK196 except for the excised AP gene —was cut from the gel.  From lane three, the 
bottom band—the smaller vector fragment containing only the wild-type pyrI gene —
was cut from the gel.  These excised DNA fragments were purified and ligated to reform 
a circular plasmid.
Lane
1 2 3 4
Figure 21.  1% Agarose/EtBr gel electrophoresis of the XmaI and XhoI restriction digest of 
pEK196 (lane 1), pEK196 undigested (lane 2), XmaI and XhoI digest of pEK592 (lane 3), and 
pEK592 undigested (lane 4).
The success of the ligation was confirmed by the performance of a second 
restriction digest in which the newly created plasmid was digested zero, one, or two 
times.        
Lane
1 2 3
Figure 22. 1% agarose/EtBr gel electrophoresis of the restriction digest products of the signal 
sequence/pyrI plasmid cut with XmaI and XhoI (lane 1), plasmid cut only with XmaI (lane 2), 
plasmid uncut (lane 3).
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Figure 22 displays that the double-cut plasmid travels farthest through the gel due 
to its lowered molecular weight, the vector cut only one time travels further than the 
circular vector due to the increased ease of mobility of a linear fragment.
After purification and over-expression of the signal sequence/pyrI plasmid, 
followed by transformation of EK1594 competent cells, the osmotic shock procedure was 
performed.  The procedure was performed on cells transformed with the signal sequence 
containing plasmid, as well as on cells transformed with wild-type pyrI plasmid 
(pEK592).  The contents of the periplasm and of the cytoplasm were isolated from each 
of these cell lines.  The isolated protein was electrophoresed on a 15% native 
polyacrylamide gel to facilitate visualization of the contents of the sample.  The gel 
revealed that ATCase regulatory chain protein was present in the cytoplasmic samples, 
but was not present to any significant extent in the periplasmic samples.  From the cells 
transformed with pEK592, the wild-type regulatory chain protein was seen, as expected, 
in the cytoplasmic samples and not in the periplasmic samples (Figure 23).
Lane
1 2 3 4 5 6 7
Figure 23. 15% Native-PAGE of the protein isolated from the periplasm of EK1594 cells 
transformed with the signal sequence / pyrI plasmid (lanes 1 and 2), protein isolated from the 
cytoplasm of these cells (lanes 3 and 4), protein isolated from the periplasm of cells transformed 
with pEK592 (lane 5), and protein isolated from the cytoplasm of these cells (lanes 6 and 7).
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The attempt at creating a regulatory chain hybrid by way of attaching an alkaline 
phosphotase signal sequence to the ATCase regulatory chain was unsuccessful.  The fact 
that the results showed regulatory chain present in the cytoplasm and not in the periplasm 
could be indicative of one of two things.  The first of these possibilities is that the signal 
sequence failed to export the regulatory chain protein to the periplasm.  This failure could 
be due to incompatibility of the regulatory chain protein with the transport mechanism, or 
could be due to accidental removal from pEK196 of DNA necessary to the signaling 
process.  The second possibility is that the regulatory chain protein was exported but was 
degraded by proteases present in the periplasm designed to recognize and destroy 
molecules that do not belong in the periplasm.  Without conducting this experiment in 
cells that have been engineered to be protease free, it is not possible to say which of these 
possibilities is correct. 
Had this experiment gone favorably, a second plasmid would have been 
constructed, attaching the same signal sequence to the K60E/K94E mutant pyrI gene, and 
cells would have been co-transformed with both the signal sequence/wild-type plasmid, 
and the signal sequence/mutant regulatory chain plasmid in an attempt to promote the 
formation of hybrid dimers.  However, as initial results were unfavorable, subsequent 
steps were not carried out.
Blocking dimer formation with a synthetic polypeptide
The synthetic pentapeptide designed to bind to the dimerization interface of the 
ATCase regulatory chain was allowed to equilibrate in a mixture with the ATCase 
regulatory chain and EDTA.  Polyacrylamide gel electrophoresis was used to compare 
the effects of this mixture with the effects of dialyzing the regulatory chain in an EDTA 
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buffer without the presence of the polypeptide.  Figure 24 displays the results of these 
dialysis experiments.   
Lane
1 2 3
Figure 24.  15% Native-PAGE of wild-type ATCase regulatory chain protein (lane 1), wild-type 
ATCase regulatory chain protein dialyzed against 10 mM EDTA (lane 2), and wild-type ATCase 
regulatory chain protein mixed with a large molar excess of synthetic pentapeptide and dialyzed 
against 10mM EDTA
An equal amount of ATCase regulatory chain was loaded into all three lanes of 
the above gel.  The lightness of the regulatory chain dimer band (bottom) in lane two as 
compared to the dimer band in lane 1 indicates that the EDTA may be causing the protein 
to cluster into large aggregates.  The fact that ATCase regulatory chain will aggregate in 
the presence of EDTA is supported by the research of Schachman et al., who found that 
monomeric regulatory chains would aggregate when EDTA was added24. Aggregated 
protein has extremely limited electrophoretic mobility due to its bulkiness, and therefore 
would result in a band at the very top of the gel as is seen in lane two.  Lane three shows 
a band that travels a distance in between that of the regulatory chain dimer and the 
aggregated protein.  It was expected that if a peptide/monomer complex formed, it would 
migrate farther than the regulatory chain dimer because it would have a lower molecular 
weight.  However, on native gels electrophoretic mobility is not governed exclusively by 
molecular weight, therefore a more conclusive method had to be devised to interpret the 
effects of the pentapeptide.
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This method was the sucrose density gradient experiments.  These experiments 
work by separating proteins with different sedimentation coefficients.  A protein’s 
sedimentation coefficient depends on its mass, its partial specific volume, and its 
frictional coefficient according to the equation, where s is the 
sedimentation coefficient, m is the mass of the protein,   is the partial specific volume of 
the protein, 	  is the density of the gradient, and f is the frictional coefficient of the 
protein, which is a measure of the protein’s shape.  The assumption can be made that the 
shape and partial specific volumes of all proteins in use are similar enough that the only 
variable being dealt with is the mass.  A more massive protein will sediment more rapidly 
than a less massive protein.  Due to this property, when the protein content of the 
fractions collected from the gradient is measured, these data provide information about 
the mass (molecular weight) of the protein species.  Knowledge of the molecular weight 
allows determination of whether the regulatory chain exists predominantly as a monomer 
or a dimer.
Molecular weights were not determined precisely, but were estimated based on 
comparison with standards of known molecular weight.  These standards are carbonic 
anhydrase, an enzyme with a molecular weight approximately equal to that of an ATCase 
regulatory chain dimer, and myoglobin, an enzyme with a molecular weight 
approximately equal to that of an ATCase regulatory chain monomer.  The fractions are 
collected starting from the top of the gradient and proceeding to the bottom.  Therefore, 
the first fractions contain protein of the smallest molecular weight, and as fraction 
number increases, molecular weight of the protein species present increases 
correspondingly.  The absorbance of each fraction was measured.  Absorbance increases 
s = m(1	) f
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proportionally to concentration.  Therefore, determining the fractions which had the 
highest absorbance provided an indication of the protein molecular weight which was 
present at the highest concentration in each protein sample.  Figure 25 is a graphical 
representation of this data.  Primarily, it gives an indication of whether the monomer or 
dimer was favored in the monomer ? dimer equilibrium.
Figure 25.  Graph depicting the absorbance at 595 nm (protein content) of fractions collected 
from the sucrose density gradients after 20 hour centrifugation period.
This graph illustrates that regulatory chain (green) or regulatory chain that has 
been dialyzed with EDTA for only a short period of time (black) migrates through the 
sucrose gradient a distance similar to that of the carbonic anhydrase, indicating that the 
regulatory chain exists here as a dimer.  EDTA dialysis for only one half hour does not 
allow sufficient time for the EDTA to cause demetallation and monomerization of the 
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regulatory chain.  However, when EDTA dialysis is allowed to proceed over a period of 
seventy-two hours (pink) monomerization does occur.  Figure 25 illustrates this by 
showing that seventy-two hour EDTA dialysis causes the regulatory chain to migrate 
through the sucrose gradient a similar distance to that of myoglobin.  Comparison of the 
line representing the sample with the polypeptide (light blue) to the sample without the 
polypeptide (pink), reveals that the polypeptide affects no changes that EDTA alone does 
not.
The results from the experiments with the pentapeptide revealed that the small 
polypeptide was not important in promoting the predominance of the regulatory chain 
monomer in equilibrium, however EDTA was important. The peptide may not have had a 
high enough affinity for the regulatory chain to be an effective competitor with 
dimerization.
The significance of EDTA is that it effectively de-metallates the regulatory chain 
protein.  According to Schachman et al.24, the role of zinc in the regulatory subunit is to 
significantly increase the interchain affinity, causing the regulatory subunit chains to 
associate fully to the dimer level.  Dialysis of the protein in a buffer containing EDTA, a 
chelating agent, complexes the zinc ions, effectively removing them from the protein and 
creating an apo- (metal free) regulatory subunit24.  Therefore, EDTA dialysis decreases 
interchain affinity, and causes a shift in the regulatory chain equilibrium towards the 
monomer.
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EDTA induced monomerization of wild-type and mutant regulatory chain subunits, 
follwed by re-dimerization.
Wild-type and K60E/K94E mutant regulatory chain were combined and dialyzed 
against EDTA.  The protein mixture was then removed from the EDTA mixture and 
dialyzed against a zinc containing buffer.  The resulting protein sample was then run on a 
polyacrylamide gel for visualization (Figure 26).  Controls were used to compare the 
protein sample to wild-type regulatory chain protein which had not been dialyzed in 
EDTA, mutant regulatory chain protein which had not been dialyzed in EDTA, wild-type 
regulatory chain protein which had been dialyzed in EDTA, mutant regulatory chain 
protein which had been dialyzed in EDTA, and a mixture of the two regulatory chain 
proteins without dialysis in EDTA.
Lane
1 2 3 4 5 6
Figure 26. 12% Native-PAGE of wild-type regulatory chain (lane 1), K60E/K94E regulatory 
chain (lane 2), 50:50 mixture of wild-type and K60E/K94E regulatory chain (lane 3), wild-type 
regulatory chain dialyzed in EDTA then in a Zn2+ containing buffer (lane 4), K60E/K94E 
dialyzed in EDTA then in a Zn2+ containing buffer (lane 5), 50:50 mixture of wild-type and 
K60E/K94E regulatory chain dialyzed in EDTA then in a Zn2+ containing buffer (lane 6).
Lanes one and two of the gel reveal that the wild-type and mutant regulatory 
proteins have bands which are distinct from each other.  The heaviest (bottom) band in 
lane two is the holo-regulatory subunit; the additional lighter bands above, represent the 
regulatory dimer having lost one or two of its zinc molecules.  Lane three shows that the 
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mixture of wild-type and K60E/K94E regulatory dimer contains bands representative of 
each of these two proteins, but no additional bands which would be representative of a 
hybrid dimer.  Lanes four and five reveal that the wild-type and K60E/K94E regulatory 
proteins individually subjected to the EDTA then zinc dialysis are not completely 
restored to the holo-regulatory subunit.  In lane six, wild-type and mutant regulatory 
protein are dialyzed in EDTA to remove zinc and promote monomerization, and then 
combined in the presence of zinc to promote reformation of dimers.  The bottom two 
bands in lane six match up with the bands resulting from the double mutant protein seen 
in lane two.  The top band in lane six matches up with the band resulting from the wild-
type protein seen in lane one.  No additional bands that could represent hybrid regulatory 
dimer can be seen in this lane, indicating that the experiment was unsuccessful.  
The results of this project suggest that the K94E/K60E mutant and wild-type
regulatory chain are incompatible for dimerization to form hybrid regulatory subunit.  
The engineered mutations may have altered the protein in a way that affected the rate or 
manner of protein folding. If the wild-type and mutant proteins do not fold into proper 
conformation at the same rate as each other, they will be less likely to dimerize 
heterogeneously.  The mutations may have made the regulatory chain much less stable or 
more prone to aggregation than the wild-type protein.  If the mutant protein is  unstable, it 
would be far less favorable for the wild-type protein to dimerize with a mutant chain as 
opposed to another stable wild-type chain.  If the mutations caused the regulatory chain 
to aggregate, these proteins would not be available for dimerization to form a hybrid.  For 
continued work on the regulatory chain hybrid project, it would be advantageous to 
design a new mutant which would compromise nucleotide binding in a manner similar to 
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the K60E/K94E mutant, but may be more compatible for dimerization with the wild-type 
protein.
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CHAPTER 4
Kinetic Characterization of ATCase mutant D141A: Results and Discussion
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To determine the effects of a mutation made to an enzyme, a series of kinetic 
assays is performed.  The results of these assays can be compared to responses of wild-
type enzyme to the same assays, in order to establish the mutant’s deviation from the 
norm.  This information can then be used to deduce the importance of the residue being 
studied in the wild-type enzyme.
For a complete characterization of a mutant enzyme, assays should be performed 
which measure the enzyme’s response to increasing concentrations of its two substrates, 
L-aspartate and carbamoyl phosphate, as well as its three nucleotide effectors, CTP, ATP, 
and CTP and UTP together.  This project reports progress towards a complete 
characterization.  L-aspartate, CTP, and ATP saturation curves have been obtained.
Asparate Saturation Curve
Figure 27. Influence of L-aspartate on D141A enzyme.  Colorimetric assays were performed at 
25° in 0.1 M tris-acetate buffer at pH 8.3 in the presence of increasing concentrations of aspartate. 
Specific activity is measured in m mols of N-carbamoyl-L-aspartate formed per hour per mg of 
ATCase.  The maximum velocity of the enzyme is 1.24 mmol/mg.  The half-saturation ([S] 0.5) 
of the enzyme is 11.54 mM Asp.
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As can be seen from the aspartate saturation curve, the specific activity of D141A 
is 1.24 mmol/ mg.  This value is significantly lower than that of wild-type ATCase, 
which is typically around 18.0 mmol/mg24.    This is a clear indication that this residue is 
critical to functioning of ATCase.  The half-saturation point, the concentration of 
aspartate required for the enzyme to reach half of its maximum velocity, is calculated to 
be 11.5 mM aspartate.  This value is similar to that of wild-type ATCase.
CTP Saturation Curve
Figure 28. Influence of CTP on D141A enzyme.  Colorimetric assay was performed at 25° in 
0.1M tris-acetate buffer at pH 8.3 in the presence of increasing concentrations of CTP.  Aspartate 
concentration was held constant at one half of the half saturation value. 
The activity of the mutant enzyme is inhibited by CTP to about 70% of its 
original level of activity.  Wild-type ATCase typically has only about 30% residual 
activity in the presence of CTP21.  CTP inhibition therefore, is partially compromised. 
The D141A mutant is inhibited by CTP to a much smaller extent than wild-type enzyme 
51
0.0 1.0 2.0 3.0 4.0
0.0
2.0
4.0
6.0
[ATP] mM
R
el
at
iv
e 
A
ct
iv
ity
is.  As with the aspartate saturation curve, it is clear here that mutating residue 141 of the 
catalytic chain has a significant effect on the overall functioning of the enzyme.
ATP Saturation Curve
Figure 29. Influence of CTP on D141A enzyme.  Colorimetric assay was performed at 25° in 
0.1M tris-acetate buffer at pH 8.3 in the presence of increasing concentrations of ATP.  Aspartate 
concentration was held constant at one half of the half saturation value.
The mutant was activated about 500% by ATP.  The behavior of the mutant seen here, in 
response to activation by ATP, is approximately similar to the behavior of the wild-type enzyme.
Without more extensive and thorough characterization of the mutant it is difficult to 
hypothesize the specific nature of ATCase’s dependence on residue 141.  It is however already 
clear that mutating the residue causes significant changes in the enzymes response to increasing 
concentrations of aspartate or of CTP.
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